TB-500 (Thymosin Beta-4) (5mg)

TB-500 (Thymosin Beta-4) Peptide

TB-500, or Thymosin Beta-4, is a synthetic analog of the endogenous Thymosin beta 4 protein, which is considered ubiquitously present in cells. The peptide belongs to a widespread family of 16 related molecules considered to exhibit a high degree of sequence conservation and localization in the majority of tissues and circulating cells.

Thymosin Beta-4 is speculated to encompass a unique peptide sequence, LKKTETQ, found between the 16th and 24th amino acids. This sequence is thought to assist in actin binding potentially. Actins are proteins believed to be vital to the cell’s cytoskeleton. They appear to maintain the cell’s structural framework and are considered by experts to be crucial for primary cellular activities, such as movement.

It is hypothesized that Thymosin Beta-4 associates with actin by attaching to globular actin (G-actin), the monomeric form of actin, before it forms filamentous actin (F-actin). This suggested interaction between Thymosin Beta-4 and G-actin might impede the polymerization process, a mechanism known as actin sequestration. This interference might potentially increase the concentration of G-actin.

The assumed inhibition of F-actin polymerization by Thymosin Beta-4 might result in alterations to the cellular cytoskeleton’s structure. These changes may impact the cell’s ability to move and undergo shape transformations.^[1] TB-500 was developed with the intention of sequestering and blocking actin polymerization in eukaryotic cells and influencing cell motility and transformation in experimental settings.

Specifications

Other Known Titles: Thymosin Beta-4

Molecular Formula: C₂₁₂H₃₅₀N₅₆O₇₈S

Molecular Weight: 4963 g/mol

Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-lle-GluLys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-LysThr-Glu-Thr-Gin-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-GluThy-lleGlu-Gin-Glu-Lys-Gin-Ala-Gly-Glu-Ser

TB-500 (Thymosin Beta-4) Research

TB-500 and Angiogenesis

TB-500 or thymosin beta-4 expression has been observed to increase fourfold to sixfold during early angiogenesis. Research suggests it may support the development of new blood vessels from existing ones, potentially facilitating accelerated tissue repair.[2] Researchers have noted that “delineating the molecular pathways impacted by Tbeta4 to promote vascular growth and remodeling may reveal novel targets for vascular disease” research. The actin-binding domain represents a short central stretch of amino acids, appearing to be involved in TB-500-mediated regulation of blood cell division, tissue repair processes, migration of endothelial cells and keratinocytes, and potentially elevated production of extracellular matrix-degrading enzymes. Preliminary studies further suggest that TB-500 may exert extracellular actions in addition to its intracellular interactions with actin, potentially influencing various cellular activities.

These proposed actions may encompass cell movement and angiogenesis — the formation of new blood vessels.[3,4] Thymosin beta-4, the naturally occurring counterpart of TB-500, is proposed to support these processes through its influence on ATP synthase enzymes located on cell surfaces, which are considered essential for generating the energy required for cellular function. This hypothesis implies a possible dual role for thymosin beta-4 in maintaining cellular structure and contributing to energy production.

TB-500 and Anti-Inflammatory Potential

TB-500 research suggests the peptide may carry potential anti-inflammatory properties.[5] Researchers have noted that “it acts by increasing angiogenesis and cell migration and is currently [studied in] wound repair.” Unlike many naturally produced growth factors, TB-500 may support endothelial and keratinocyte migration while appearing not to bind to the extracellular matrix. Its comparatively low molecular weight is suggested to facilitate relatively long-distance travel through tissues, with study findings generally proposing that the peptide’s principal action involves regulation of actin polymerization and function.

Recent research suggests TB-500 may elevate levels of microRNA-146a (miR-146a), which may act as an inhibitory regulator within certain cellular communication pathways closely linked to inflammatory processes — involving cytokines such as interleukin-1 receptor-associated kinase 1 (IRAK1) and tumor necrosis factor receptor-associated factor 6 (TRAF6). Researchers hypothesized this as one possible mechanism of TB-500 action, observing that miR-146a inhibition appeared to prevent thymosin beta-4’s suppression of IRAK1 and TRAF6 — indicating a possible anti-inflammatory mechanism. This raises the potential for TB-500 to influence inflammation-related cellular signaling through modulation of miR-146a, IRAK1, and TRAF6 interactions.[6]

TB-500 and Muscle Cell Survival

Preliminary investigations suggest that TB-500 may potentially support cardiac cell repair in experimental settings. Some evidence indicates that cardiac fibroblasts — connective tissue cells within the heart — may undergo transformation into cells resembling cardiomyocytes, the muscle cells recognized as responsible for cardiac contractions.[7] In vitro research has additionally proposed that TB-500, when used alongside cardiac reprogramming approaches, may cooperatively attenuate cardiac cell damage and support recovery through activation of endogenous cells within the heart region.

Further investigative studies in murine models involving coronary artery ligation have suggested that TB-500 may increase levels of integrin-linked kinase (ILK) and protein kinase B (Akt) — enzymes considered vital in cellular signaling pathways and proposed to play important roles in the early survival and repair of cardiomyocytes — potentially enhancing the cardiac tissue regeneration process.[8]

TB-500 and Injury Recovery

Researchers hypothesize that TB-500 may influence cytokine production in ways that could theoretically support injury recovery.[9] Observations following experimental testing suggest that TB-500 may increase expression of interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) mRNA in the corneal tissues of injured murine models. Following alkali-induced injury specifically, TB-500 exposure is proposed to potentially reduce levels of chemoattractants such as macrophage inflammatory protein-2 (MIP-2) and keratinocyte chemoattractant (KC), potentially resulting in decreased infiltration of polymorphonuclear neutrophils (PMNs) — white blood cells integral to the inflammatory response.

Researchers further speculate that TB-500 may interact with nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) signaling pathways in the cornea, pointing to possible anti-inflammatory capacity. TB-500 is additionally believed to possess anti-apoptotic properties, with cellular models demonstrating that overexpression appears to correlate with increased cell proliferation, reduced basal apoptosis, and enhanced resistance to apoptosis-inducing agents.

It is proposed that TB-500 may inhibit apoptosis in corneal epithelial cells by blocking caspase activity — enzymes playing a central role in cell death — and preventing mitochondrial release of the pro-apoptotic protein bcl-2. The proposed anti-apoptotic mechanism may involve reduction of early cell death signals and potential activation of the survival kinase Akt through interactions with proteins including the cysteine-histidine-rich protein PINCH and integrin-linked kinase, both understood to be involved in cell survival signaling pathways. If validated, these mechanisms may collectively contribute to the enhanced recovery observed in various tissue injury models exposed to TB-500.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References